secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2021-08-16T23:59:59+00:00
Accession:  0001193125-21-247691
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences CMO Howard Levy retires, transitions to consultant through Sept 2022
--------------------------------------------------------------------------------

- Howard Levy retired as CMO effective Aug 15, 2021; consulting role until Sept 30, 2022.
- Consulting at customary hourly rate; vested options exercisable 90 days after termination.
- Levy to provide consulting on hemophilia programs; non-compete in Factor VIIa/IX and complement areas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000119312521247691/0001193125-21-247691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000119312521247691/d193376d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-247691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer